Publication | Closed Access

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Open LabelMedicineCancer GrowthPathologyCancer GenomicsCancer TreatmentCancer GeneticsGefitinib Versus CisplatinOncologyRadiation OncologyLung CancerMolecular OncologyPhase 3